Stemline Therapeutics

New York,  NY 
United States
https://stemlinevirtualbooth.com/asco2021

• Booth: 22115

Stemline Therapeutics, part of the Menarini Group, is focused on the development and commercialization of novel oncology therapeutics. ELZONRIS®, a CD-123 targeted therapy, is approved in the US for treatment of first-line or R/R patients with BPDCN, and approved in Europe for first-line patients with BPDCN. Ongoing ELZONRIS clinical trials in chronic myelomonocytic leukemia (CMML), MF and AML. Our pipeline includes: felezonexor (SL-801; XPO1 inhibitor; Phase 1), SL-1001 (novel RET inhibitor, pre-IND), SL-701 (immunotherapeutic; Phase 2 in GBM complete), and SL-901 (kinase inhibitor; Phase 1).

Brands: https://stemline.com/wp-content/uploads/2021/04/ASCO_Banner.jpg

 Show Specials

• ELZONRIS (Apr 30, 2021)
  <div style="padding:56.25% 0 0 0;position:relative;"><iframe src="https://player.vimeo.com/video/543710099?badge=0&amp;autopause=0&amp;player_id=0&amp;app_id=58479" frameborder="0" allow="autoplay; fullscreen; picture-in-picture" allowfullscreen style="position:absolute;top:0;left:0;width:100%;height:100%;" title="ELZONRIS Treatment for BPDCN"></iframe></div><script src="https://player.vimeo.com/api/player.js"></script>

 Press Releases

• ELZONRIS US Full Prescribing Information (Apr 30, 2021)
  https://www.elzonris.com/hcp/Content/documents/ELZONRIS_US_Full_Prescribing_Information.pdf

• ELZONRIS Website (Apr 30, 2021)
  https://www.elzonris.com/hcp

• Stemline Website (Apr 30, 2021)
  www.stemline.com